LB Pharmaceuticals LBRX 深 沪
交易中 09-25 11:23:57 美东时间
37.47
-0.330
-0.87%
华盛通- 最 高38.57
- 今 开37.85
- 成交量 8.24万股
- 最 低 37.09
- 昨 收 37.80
- 总市值 12.09亿
- 52周最高 50.16
- 市盈率 静 --
- 换手率 0.26%
- 52周最低 14.3166
- 委 比 19.05%
- 总股本 3225.92万
- 历史最高 50.16
- 量 比 0.83
- 振 幅 3.92%
- 历史最低 13.36
- 每 手 1
- 风险率 9.71%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical Officer
LB Pharmaceuticals Inc announced the appointment of Susan G. Kozauer, M.D., as Chief Medical Officer. Dr. Kozauer brings over two decades of experience in neuropsychiatric drug development, including schizophrenia, mood disorders, and neurodegenerative diseases. She previously led clinical development at Intra-Cellular Therapies and Centessa Pharmaceuticals. LB Pharmaceuticals is advancing its Phase 3 NOVA-2 trial for LB-102, a potential first be...
09-15 12:00
LB Pharmaceuticals Appoints Joseph Miller CFO
LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced the appointment of Joseph Miller as Chief Fin...
09-03 20:07
LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer
LB Pharmaceuticals has appointed Joseph Miller as its Chief Financial Officer. With over 20 years of experience in biopharmaceutical finance, Miller brings expertise in financial strategy, operations, and organizational growth. His appointment coincides with the company's pivotal NOVA-2 clinical trial for LB-102, a potential schizophrenia treatment. Miller's leadership at Aurinia Pharmaceuticals and Avalo Therapeutics, where he successfully scale...
09-03 12:00
美股大行评级 | 首予买入！Jersey Mike's获13家大行评级；大摩、富国银行齐上调迈威尔科技目标价，最高升至310美元
今日重点评级关注：Truist Securities：维持CoreWeave"买入"评级，目标价从155美元升至165美元；百德：维持亚德诺"跑赢大市"评级，目标价从450美元升至675美元
08-25 11:47
Analog Devices To Rally Around 81%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Baird cut the price target for Chipotle Mexican Grill Inc (NYSE:CMG) from $44 to $40. Baird analyst Chris O’Cu...
08-24 21:30
HC Wainwright & Co. Maintains Buy on LB Pharmaceuticals, Raises Price Target to $60
HC Wainwright & Co. analyst Raghuram Selvaraju maintains LB Pharmaceuticals (NASDAQ:LBRX) with a Buy and raises the price target from $45 to $60.
08-24 18:06
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
BMO Capital Maintains Outperform on LB Pharmaceuticals, Raises Price Target to $54
BMO Capital analyst Malcolm Hoffman maintains LB Pharmaceuticals (NASDAQ:LBRX) with a Outperform and raises the price target from $46 to $54.
08-12 20:05
LB Pharmaceuticals Q2 EPS $(1.71) Misses $(0.80) Estimate
LB Pharmaceuticals (NASDAQ:LBRX) reported quarterly losses of $(1.71) per share which missed the analyst consensus estimate of $(0.80) by 113.75 percent. This is a 87.41 percent increase over losses of $(13.58) per share from the same period last year.
08-11 20:05
LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
LB Pharmaceuticals announced the accelerated timeline for top-line data from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia, expected in the first half of 2027. The company also plans to expand LB-102's pipeline into new neuropsychiatric indications, supported by clinical and real-world experience from amisulpride. As of June 30, 2026, the company had $327.8 million in cash, cash equivalents, and marketable securities, plus $150 mill...
08-11 12:00
